Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gedeon Richter Strikes $16.5m Global Tocilizumab Deal

Agreement For Biosimilar To Actemra/RoActemra Reached With Taiwan’s Mycenax

Executive Summary

Gedeon Richter has struck a deal worth $16.5m with Taiwan’s Mycenax for global rights to a tocilizumab biosimilar version of Actemra/RoActemra, setting a date for planned launches in the EU, Japan, Canada and Australia.

You may also be interested in...



Roche Makes Tocilizumab Launch Prediction As Biosimilars Progress

Roche gave small insight into its expectations around biosimilar competition for its Actemra/RoActemra (tocilizumab) treatment for inflammatory diseases. Extraordinary demand for the biologic led sales to skyrocket by 143% in the third quarter and caused supply constraints for the originator.

Fresenius Kabi Makes Progress On Tocilizumab

Fresenius Kabi has reported positive Phase I data for its MSB11456 proposed tocilizumab biosimilar rival to Actemra/Ro-Actemra, against the backdrop of shortages for the brand which is being used in some regions to treat COVID-19.

Biogen and Bio-Thera Reveal Tocilizumab Progress

Biogen and Bio-Thera Solutions have reported positive results from a Phase III trial for their BAT1806 proposed biosimilar tocilizumab rival to Actemra. The milestone has triggered a $30m payment from Biogen under the pair’s development deal.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB149850

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel